The estimated Net Worth of Mehdi Gasmi is at least $2.07 Million dollars as of 20 July 2020. Mehdi Gasmi owns over 5,000 units of Adverum Biotechnologies Inc stock worth over $1,964,477 and over the last 8 years he sold ADVM stock worth over $0. In addition, he makes $106,379 as Director at Adverum Biotechnologies Inc.
Sign up
Mehdi Gasmi ADVM stock SEC Form 4 insiders trading
Mehdi has made over 8 trades of the Adverum Biotechnologies Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 5,000 units of ADVM stock worth $24,000 on 20 July 2020.
The largest trade he's ever made was exercising 40,000 units of Adverum Biotechnologies Inc stock on 5 May 2020 worth over $192,000. On average, Mehdi trades about 6,875 units every 12 days since 2017. As of 20 July 2020 he still owns at least 279,442 units of Adverum Biotechnologies Inc stock.
You can see the complete history of Mehdi Gasmi stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mehdi Gasmi biography
Dr. Mehdi Gasmi Ph.D. serves as Director of the Company. Dr. Gasmi served as our president and chief scientific officer since October 2018. From February 2017, to October 2018, he served as our chief science and technology officer. Previously, he served as our interim chief scientific officer from July 2015 to February 2018, senior vice president, pharmaceutical development from May 2015 to July 2015, and as vice president, pharmaceutical development from November 2013 to May 2015. From December 2011 to November 2013, as principal of ClinVec Solutions, LLC, Dr. Gasmi provided adeno-associated virus (“AAV”) and lentiviral gene therapy consulting services to various companies, including to us, from June 2013 to October 2013. Prior to that, Dr. Gasmi oversaw production of clinical batches of recombinant AAV and lentiviral gene therapy products for both Genethon, a nonprofit gene therapy company, where he served as vice president of biomanufacturing from July 2009 to December 2011, and for Ceregene, a gene therapy company, where he served as senior director, product development from December 2001 to June 2009. Dr. Gasmi obtained his M.S. and his Ph.D. in Biochemistry from the Claude Bernard University in Lyon, France.
What is the salary of Mehdi Gasmi?
As the Director of Adverum Biotechnologies Inc, the total compensation of Mehdi Gasmi at Adverum Biotechnologies Inc is $106,379. There are 12 executives at Adverum Biotechnologies Inc getting paid more, with Leone Patterson having the highest compensation of $2,830,320.
How old is Mehdi Gasmi?
Mehdi Gasmi is 53, he's been the Director of Adverum Biotechnologies Inc since 2019. There are 9 older and 8 younger executives at Adverum Biotechnologies Inc. The oldest executive at Adverum Biotechnologies Inc is Richard Spivey, 69, who is the Independent Director.
What's Mehdi Gasmi's mailing address?
Mehdi's mailing address filed with the SEC is C/O ADVERUM BIOTECHNOLOGIES, INC., 800 SAGINAW DRIVE, REDWOOD CITY, CA, 94063.
Insiders trading at Adverum Biotechnologies Inc
Over the last 8 years, insiders at Adverum Biotechnologies Inc have traded over $1,591,374 worth of Adverum Biotechnologies Inc stock and bought 912,973 units worth $4,153,055 . The most active insiders traders include Patrick Machado, Braden Michael Leonard und Thomas Woiwode. On average, Adverum Biotechnologies Inc executives and independent directors trade stock every 40 days with the average trade being worth of $200,186. The most recent stock trade was executed by Braden Michael Leonard on 30 July 2024, trading 85,800 units of ADVM stock currently worth $613,470.
What does Adverum Biotechnologies Inc do?
adverum (nasdaq: advm) is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. we are advancing the development of a robust pipeline of gene therapies that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (a1at) deficiency and hereditary angioedema (hae) as well as wet age-related macular degeneration (wamd). leveraging our next-generation adeno-associated virus (aav)-based directed evolution platform, we generate gene therapies designed to provide durable efficacy by inducing sustained expression of a therapeutic protein.
What does Adverum Biotechnologies Inc's logo look like?
Complete history of Mehdi Gasmi stock trades at Adverum Biotechnologies Inc
Adverum Biotechnologies Inc executives and stock owners
Adverum Biotechnologies Inc executives and other stock owners filed with the SEC include:
-
Leone Patterson,
President -
Thomas Leung,
Chief Financial Officer -
Aaron Osborne,
Chief Medical Officer -
Dr. Laurent Fischer,
Pres, CEO, Interim CMO & Director -
Dr. Brigit Riley Ph.D.,
Chief Scientific Officer -
Rekha Hemrajani,
Independent Director -
James Scopa,
Independent Director -
Mark Lupher,
Independent Director -
Patrick Machado,
Independent Chairman of the Board -
Richard Spivey,
Independent Director -
Eric Carter,
Independent Director -
Thomas Woiwode,
Independent Director -
Mehdi Gasmi,
Director -
Myesha Lacy,
Vice President, Investor Relations and Corporate Communications -
Scott Whitcup,
Independent Director -
Peter Soparkar,
Chief legal officer -
Christopher Morrison,
Vice President - Process Development -
Thomas Kochy,
Vice President - Commercial and Program Strategy -
Heikki Jouttijarvi,
Vice President - Manufacturing -
Angela Thedinga,
Chief Technology Officer -
Laurent Fischer,
Chief Executive Officer, Director -
Carla Fiankan,
Sr. VP of Regulatory Affairs -
Nancy E. Pecota,
Principal Accounting Officer -
John W. Rakow J.D.,
Sr. VP, Gen. Counsel & Acting CFO -
Anand Reddi,
VP, Head of Corp. Strategy & External Affairs and Engagement -
Michael Steel,
Sr. VP of Quality -
Dr. Jim Wang Ph.D.,
Sr. VP & Head of Regulatory Affairs -
Dena House,
Sr. VP of HR, Organizational Devel. & Learning -
Kishor Peter Soparkar J.D.,
Chief Operating Officer -
Dr. Rupert D'Souza M.B.A., Ph.D.,
Chief Financial Officer -
Steven Daniel Schwartz,
Director -
Samuel B. Barone,
SVP, Clinical Development -
Athena Countouriotis,
SVP, Chief Medical Officer -
Mitchell H. Finer,
Director -
Carlo Russo,
EVP and Chief Medical Officer -
Jennifer C. Cheng,
General Counsel -
Amber Salzman,
President and CEO -
Paul B Cleveland,
Chief Executive Officer -
Richard Beckman,
Chief Medical Officer -
Szilard Kiss,
-
Soo Hong,
-
Rabia Gurses Ozden,
Chief Medical Officer -
Linda M Rubinstein,
CHIEF FINANCIAL OFFICER -
Dawn Svoronos,
-
Reed Vaughn Tuckson,
-
Rupert D'souza,
Chief Financial Officer -
Julie Clark,
Chief Medical Officer -
Setareh Seyedkazemi,
CHIEF DEVELOPMENT OFFICER -
Braden Michael Leonard,
-
Brigit Riley,
Chief Scientific Officer -
John Rakow,
SVP, Genl Counsel, Acting CFO -
C. David Nicholson,,